ROCKVILLE, MD – Vanda Pharmaceuticals Inc. (Nasdaq:VINDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, says former acting U.S. Surgeon General Steven Galson to its board.
Mihael H. Polymeropoulos, M.D., president and CEO of Vanda, said, “Dr. Galson’s experience as the former Acting U.S. Surgeon General and Deputy Director and Director of the Center for Drug Evaluation and Research will add tremendous value to the board.”
We don’t generally note board appointments, but nabbing a former Surgeon General–even an acting one–is something of a coup.
Currently, Dr. Galson is the Senior Vice President for the Civilian Health Operation at Science Applications International Corporation (SAIC). He has also held executive positions in the U.S. Environmental Protection Agency, U.S. Department of Energy, and the Centers for Disease Control and Prevention’s National Institute for Occupational Safety and Health.
That sort of background has to be a plus for any company in the highly regulated pharmaceutical industry.